RXi Pharmaceuticals Presents New Preclinical RNAi Data at the Keystone Mechanism and Biology of Silencing Conference

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNA interference (RNAi) based therapeutic discovery and development, today announced that new preclinical data using proprietary self-delivering RNAi (sd-rxRNA™) compounds, including RXI-109, will be presented at the Keystone Symposia’s Mechanism and Biology of Silencing conference being held March 20-25, 2011 in Monterey, California.

MORE ON THIS TOPIC